Arne Ring

List of Publications by Year
in descending order

53	1,801	331259 21	264894 42
papers	citations	h-index	g-index

55	55	55	1933
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evaluation of the drugâ€drug interaction potential of treosulfan using a physiologicallyâ€based pharmacokinetic modelling approach. British Journal of Clinical Pharmacology, 2022, 88, 1722-1734.	1.1	4
2	Assessing consistency in clinical trials with two subgroups and binary endpoints: A new test within the logistic regression model. Statistics in Medicine, 2020, 39, 4551-4573.	0.8	1
3	The potential of the estimands framework for clinical pharmacology trials: Some discussion points. British Journal of Clinical Pharmacology, 2020, 86, 1240-1247.	1.1	3
4	Sample size determination in bioequivalence studies using statistical assurance. British Journal of Clinical Pharmacology, 2019, 85, 2369-2377.	1.1	14
5	Evaluation of Markov chains to describe movements on tiling. Open Journal of Mathematical Sciences, 2019, 3, 358-381.	0.7	2
6	How publication guidelines for clinical pharmacology trials may help to accelerate knowledge transfer. British Journal of Clinical Pharmacology, 2018, 84, 611-614.	1.1	2
7	Equivalence Tests in Subgroup Analyses. ICSA Book Series in Statistics, 2018, , 201-238.	0.0	1
8	Statistical reporting of clinical pharmacology research. British Journal of Clinical Pharmacology, 2017, 83, 1159-1162.	1.1	7
9	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 877-886.	5.5	245
10	Infarct size following complete revascularization in patients presenting with STEMI: a comparison of immediate and staged in-hospital non-infarct related artery PCI subgroups in the CvLPRIT study. Journal of Cardiovascular Magnetic Resonance, 2017, 18, 85.	1.6	9
11	A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio^{Â®}) in cardiac surgery: the REVAKIâ€1 study. British Journal of Clinical Pharmacology, 2017, 83, 709-720.	1.1	11
12	Trial protocol for a randomised controlled trial of red cell washing for the attenuation of transfusion-associated organ injury in cardiac surgery: the REDWASH trial. Open Heart, 2016, 3, e000344.	0.9	4
13	19â€...The randomised complete vs. lesion only primary PCI trial â€“ cardiovascular MRI substudy (CVLPRIT-CMR). Heart, 2015, 101, A10-A11.	1.2	0
14	A randomised controlled trial of six weeks of home enteral nutrition versus standard care after oesophagectomy or total gastrectomy for cancer: report on a pilot and feasibility study. Trials, 2015, 16, 531.	0.7	52
15	Cluster randomised trial of a tailored intervention to improve the management of overweight and obesity in primary care in England. Implementation Science, 2015, 11, 77.	2.5	9
16	Complete Versus Lesion-Only Primary PCI. Journal of the American College of Cardiology, 2015, 66, 2713-2724.	1.2	43
17	Bioequivalence of Linagliptin 5â€‰mg Once Daily and 2.5â€‰mg Twice Daily: Pharmacokinetics and Pharmacodynamics in an Open-label Crossover Trial. Drug Research, 2014, 64, 269-275.	0.7	4
18	Indirect bioequivalence assessment using network meta-analyses. European Journal of Clinical Pharmacology, 2014, 70, 947-955.	0.8	4

#	Article	IF	Citations
19	Evaluation of a tailored intervention to improve management of overweight and obesity in primary care: study protocol of a cluster randomised controlled trial. Trials, 2014, 15, 82.	0.7	16
20	Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tablets. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 537-48.	0.3	5
21	Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 549-63.	0.3	3
22	The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Cardiovascular Diabetology, 2013, 12, 70.	2.7	37
23	Dabigatran Does Not Prolong the QT Interval with Supratherapeutic Exposure: a Thorough QT Study in Healthy Subjects. Clinical Drug Investigation, 2013, 33, 333-342.	1.1	6
24	Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. American Heart Journal, 2013, 166, 983-989.e7.	1.2	116
25	Evaluation of a Self-Administered Oral Glucose Tolerance Test. Diabetes Care, 2013, 36, 1483-1488.	4.3	14
26	Delayed Effects in the Exposure-Response Analysis of Clinical QTc Trials. Journal of Biopharmaceutical Statistics, 2012, 22, 387-400.	0.4	7
27	Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus. Diabetes Therapy, 2012, 3, 10.	1.2	46
28	Pharmacokinetics of linagliptin in subjects with hepatic impairment. British Journal of Clinical Pharmacology, 2012, 74, 75-85.	1.1	63
29	Author response to letter from Snyder et al. regarding manuscript entitled â€˜Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidaseâ€4 inhibitor, linagliptinâ€™ by Graefeâ€Mody et al.. Diabetes, Obesity and Metabolism, 2012, 14, 671-672.	2.2	0
30	Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. International Journal of Clinical Pharmacology and Therapeutics, 2012, 50, 889-895.	0.3	8
31	Effect of Multiple Oral Doses of Linagliptin on the Steady-State Pharmacokinetics of a Combination Oral Contraceptive in Healthy Female Adults. Clinical Drug Investigation, 2011, 31, 643-653.	1.1	23
32	Assessment of the Pharmacokinetic Interaction between the Novel DPP-4 Inhibitor Linagliptin and a Sulfonylurea, Glyburide, in Healthy Subjects. Drug Metabolism and Pharmacokinetics, 2011, 26, 123-129.	1.1	34
33	The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2011, 13, 542-550.	2.2	50
34	Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*. Diabetes, Obesity and Metabolism, 2011, 13, 939-946.	2.2	163
35	The DPPâ€4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. British Journal of Clinical Pharmacology, 2011, 72, 39-50.	1.1	31
36	A Randomized, Open-Label, Crossover Study Evaluating the Effect of Food on the Relative Bioavailability of Linagliptin in Healthy Subjects. Clinical Therapeutics, 2011, 33, 1096-1103.	1.1	20

#	Article	IF	Citations
37	Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics, 2011, 36, 17-24.	0.6	39
38	Mixed models for data from thorough QT studies: part 1. assessment of marginal QT prolongation. Pharmaceutical Statistics, 2011, 10, 265-276.	0.7	10
39	Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics, 2011, 49, 300-310.	0.3	19
40	Statistical models for heart rate correction of the QT interval. Statistics in Medicine, 2010, 29, 786-796.	0.8	11
41	Linagliptin (BIâ€ƒ1356), a potent and selective DPPâ€4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Typeâ€ƒ2 diabetes. Diabetic Medicine, 2010, 27, 1409-1419.	1.2	110
42	Statistical Characterization of QT Prolongation. Journal of Biopharmaceutical Statistics, 2010, 20, 543-562.	0.4	8
43	Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5â€‰mgâ€“10â€‰mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects. Clinical Pharmacokinetics, 2010, 49, 829-840.	1.6	45
44	Residuals and Outliers in Replicate Design Crossover Studies. Journal of Biopharmaceutical Statistics, 2010, 20, 835-849.	0.4	11
45	Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. International Journal of Clinical Pharmacology and Therapeutics, 2010, 48, 367-374.	0.3	36
46	Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics, 2010, 48, 652-661.	0.3	27
47	Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidaseâ€4 inhibitor in male type 2 diabetes patients. Diabetes, Obesity and Metabolism, 2009, 11, 786-794.	2.2	161
48	Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Current Medical Research and Opinion, 2009, 25, 1963-1972.	0.9	58
49	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers. Journal of Clinical Pharmacology, 2008, 48, 1171-1178.	1.0	124
50	Pharmacokinetic and Safety Evaluation of BILR 355, a Second-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2008, 52, 4300-4307.	1.4	19
51	Ibuprofen Extrudate, a Novel, Rapidly Dissolving Ibuprofen Formulation: Relative Bioavailability Compared to Ibuprofen Lysinate and Regular Ibuprofen, and Food Effect on All Formulations. Journal of Clinical Pharmacology, 2005, 45, 1055-1061.	1.0	54
52	Sensitivity of empirical metrics of rate of absorption in bioequivalence studies. Pharmaceutical Research, 2000, 17, 583-588.	1.7	4
53	Interpretation of General Measures of Distribution Kinetics in Terms of a Mammillary Compartmental Model. Journal of Pharmaceutical Sciences, 1997, 86, 1491-1493.	1.6	8